Get the Stockscreener App
97.28
0.61%
0.59
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $97.28, with a volume of 4.77M.
It is up +0.61% in the last 24 hours and down -11.94% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$96.69
Open:
$97.25
24h Volume:
4.77M
Relative Volume:
0.50
Market Cap:
$168.42B
Revenue:
$46.59B
Net Income/Loss:
$5.41B
P/E Ratio:
31.44
EPS:
3.0938
Net Cash Flow:
$7.38B
1W Performance:
-3.96%
1M Performance:
-11.94%
6M Performance:
-5.44%
1Y Performance:
-26.86%
1-Day Range:
$95.06
$97.53
1-Week Range:
$95.06
$101.76
52-Week Range:
$81.97
$135.37
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
97.33 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.39 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.46 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.82 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.53 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott settled a government infant formula lawsuit for nearly $385 million. - Claim Depot
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
In 1935, An Illinois Secretary Bought 3 Shares Of Her Company's Stock For $180. She Never Sold A Single Share And Always Reinvested Dividends. By The Time She Died In 2010 Her 3 Abbott Shares Had Turned Into $7.2 Million. - 247wallst.com
Abbott Laboratories’ Quarterly Earnings Preview: What You Need to Know - Barchart.com
Abbott rolls out SimpleScreen CRC blood test across the US - Medical Device Network
Abbott launches SimpleScreen CRC for Abbott Laboratories stock - AD HOC NEWS
Abbott Laboratories stock pre-market at EUR 87.30: plus 0.29 percent - AD HOC NEWS
DOJ Announces $385 Million Settlement to Resolve False Claims Allegations over Abbott Laboratories Baby Formula - MedLearn Publishing
CG Abbott plant included in $385M federal settlement - PinalCentral.com
Abbott (ABT) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Abbott (ABT) Stock May Be 25% Stretched After Biosensor Market Forecast - Simply Wall Street
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
Abbott Labs launches blood test to screen for colorectal cancer - Kenosha News
Mississippi receives $771K in Abbott formula settlement - wjtv.com
AG Fitch Announces False Claims Settlement with Abbott Laboratories - MageeNews.com
Mississippi to receive more than $771K in $384 million Abbott Laboratories settlement - Darkhorse Press
Abbott Laboratories (ABT) Launches SimpleScreen CRC As Fair Value Stays In Focus - Yahoo! Finance Canada
Mississippi to Receive $771K in $384M False Claims Settlement with Abbott Laboratories - tippahnews.com
Abbott Launches Simplescreen Crc Blood Test in the U.S - marketscreener.com
Abbott launches Freenome’s colorectal cancer screening test - MedTech Dive
In 1935, Grace Groner, a secretary, invested $180 in her employer Abbott; 75 years later, it had grown to - The Economic Times
Abbott Laboratories (NYSE:ABT): Are Investors Getting Over Their Scepticism Over The Company's Bold US$21bn Bet On Exact Sciences? - Stocks Down Under
Form 4 Abbott Laboratories For: 29 September By Investing.com - Investing.com UK
Abbott Laboratories stock at USD 100.95 on September 28, 2026 - AD HOC NEWS
Abbott lawsuit alleges spinal cord stimulators can fail, worsen nerve damage - Top Class Actions
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032 - GlobeNewswire Inc.
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? - Yahoo Finance
Abbott Laboratories Lobbying Profile, 2003 - OpenSecrets
3 Dividend Stocks To Watch As High Rates Test Defensive Shares - Simply Wall Street
Form 4 Abbott Laboratories For: 25 September By Investing.com - Investing.com India
At $103.99 a share, an Abbott Laboratories (ABT) director delivered or withheld shares for exercise costs or taxes. - Stock Titan
Abbott Laboratories stock falls 2.32 percent below yearly high effects? no - AD HOC NEWS
Is Abbott Laboratories (NYSE:ABT) Facing a Real Market Test? - Kalkine Media
Abbott Laboratories stock loses 1.82 percent before the bell - ad-hoc-news.de
How Lingo Partnership Will Impact Abbott Stock (ABT) - Simply Wall Street
Abbott to pay nearly $385 million to settle infant formula allegations - ConsumerAffairs
Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery - Yahoo Finance
Abbott Laboratories stock reports Q2 growth and earnings beat - AD HOC NEWS
Abbott Laboratories stock rises 0.69 percent ahead of the open - AD HOC NEWS
Abbott partners with Berry Street to add nutrition coaching to Lingo - Drug Delivery Business
Abbott Laboratories stock ends the day 0.69 percent higher at USD 103.69 - AD HOC NEWS
Abbott Laboratories: A Strong Business At A Fair Price (NYSE:ABT) - Seeking Alpha
Sinocare Asks Court To Rule Device Won't Infringe Abbott IP - Law360
What Makes Abbott Laboratories (ABT) an Attractive Opportunity? - Yahoo Finance
Abbott and Berry Street team up on personalized nutrition tracking - marketscreener.com
Is Abbott Laboratories (ABT) Still Undervalued On Volt’s First US And Canada Procedures? - Simply Wall Street
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Abbott and Berry Street partner to combine gluc... - Pluang
A 15% discount on Abbott's four-week glucose-monitor plans will go to Berry Street users. - Stock Titan
Abbott Laboratories stock gains 1.12 percent as settlement weighs - AD HOC NEWS
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.09%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):